<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746733</url>
  </required_header>
  <id_info>
    <org_study_id>SPD489-113</org_study_id>
    <nct_id>NCT00746733</nct_id>
  </id_info>
  <brief_title>Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Four Period Crossover Drug Interaction Study to Evaluate the Pharmacokinetic Profiles of VYVANSE™ and ADDERALL XR When Each is Administered Alone and in Combination With the Proton Pump Inhibitor Prilosec OTC™ in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR
      with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how
      much of the drug is absorbed into the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>0 through 96 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</measure>
    <time_frame>Pre-dose, 2 and 8 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Vyvanse (LDX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall XR (AXR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine Dimesylate</intervention_name>
    <description>50mg capsule</description>
    <arm_group_label>Vyvanse (LDX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall XR (mixed salts amphetamine)</intervention_name>
    <description>20mg capsule</description>
    <arm_group_label>Adderall XR (AXR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers, age 18 to 45 inclusive at the time of consent.

          2. Male, or non-pregnant, non-lactating female

          3. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG)
             pregnancy test at Screening, and a negative urine pregnancy test on Day -1 after
             checking into the clinic the day before the first dose of investigational product.

          4. Body Mass Index (BMI) between 20.0 and 30.0 kg/m² inclusive. This inclusion criterion
             will only be assessed at the first screening visit.

          5. Satisfactory medical assessment with no significant or relevant abnormality in medical
             history, physical examination (PE), vital signs and laboratory evaluation

          6. Normal or clinically insignificant Screening ECG findings as assessed by the
             Investigator.

          7. Ability to swallow investigational products.

        Exclusion Criteria:

          1. Current or recurrent disease that could affect the action, absorption or disposition
             of the investigational products, or could affect clinical or laboratory assessments.

          2. Current or relevant previous history of physical or psychiatric illness, any medical
             disorder that may require treatment or make the subject unlikely to fully comply with
             the requirements of the study or complete the study, or any condition that presents
             undue risk from the investigational products or study procedures.

          3. Significant illness, as judged by the Investigator, within 2 weeks of the first dose
             of investigational product.

          4. History of significant anxiety, tension or agitation as assessed by the Investigator.

          5. History of or current diagnosis of glaucoma.

          6. History of a seizure disorder (other than infantile febrile seizures), any tic
             disorder or a current diagnosis and/or known family history of Tourette's Disorder.

          7. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural
             cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary
             artery disease, transient ischemic attack or stroke or other serious cardiac problems
             that may place them at increased vulnerability to the sympathomimetic effects of a
             stimulant drug.

          8. History of controlled or uncontrolled hypertension or a resting sitting systolic blood
             pressure &gt;139mmHg or diastolic blood pressure &gt;89mmHg.

          9. Known family history of sudden cardiac death or ventricular arrhythmia.

         10. Currently considered a suicide risk, has previously made a suicide attempt or has a
             prior history of, or is currently demonstrating suicidal ideation.

         11. Current use of any medication (including prescription, over the counter [OTC], herbal
             or homeopathic preparations) with the exception of hormonal replacement therapy or
             hormonal contraceptives (Current use is defined as use within 14 days of first dose of
             investigational product).

         12. Use of any medication known to inhibit or induce the CYP450 enzymes responsible for
             the metabolism of the investigational products within 14 days of first dose of
             investigational product.

         13. Known or suspected intolerance or hypersensitivity to the investigational product(s),
             closely related compounds or any of the stated ingredients.

         14. History of alcohol or other substance abuse within the last year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C. Lasseter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology of Miami, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA recall information</description>
  </link>
  <results_reference>
    <citation>Haffey MB, Buckwalter M, Zhang P, Homolka R, Martin P, Lasseter KC, Ermer JC. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009 Sep;121(5):11-9. doi: 10.3810/pgm.2009.09.2048.</citation>
    <PMID>19820270</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <results_first_submitted>October 14, 2009</results_first_submitted>
  <results_first_submitted_qc>October 14, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2009</results_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gerald Tremblay, M.D.</name_title>
    <organization>Shire Pharmaceutical</organization>
  </responsible_party>
  <keyword>Drug</keyword>
  <keyword>Interaction</keyword>
  <keyword>Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
    <mesh_term>Adderall</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Open-label, randomized, four period crossover</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vyvanse First</title>
          <description>Vyvanse 50mg dosed once in the first intervention, Adderall XR 20 mg dosed once in the second intervention, Vyvanse 50mg + Prilosec OTC 40mg dosed once in the third intervention, Adderall XR 20mg + Prilosec OTC 40mg dosed once in the fourth intervention.</description>
        </group>
        <group group_id="P2">
          <title>Adderall XR First</title>
          <description>Adderall XR 20 mg dosed once in the first intervention, Vyvanse 50mg dosed once in the second intervention, Adderall XR 20mg + Prilosec OTC 40mg dosed once in the third intervention, Vyvanse 50mg + Prilosec OTC 40mg dosed once in the fourth intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>Pharmacokinetic (PK) population defined as all subjects who have evaluable concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
          <population>Pharmacokinetic (PK) population defined as all subjects who have evaluable concentration-time profiles.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.04" spread="13.971"/>
                    <measurement group_id="O2" value="28.66" spread="7.174"/>
                    <measurement group_id="O3" value="46.34" spread="9.710"/>
                    <measurement group_id="O4" value="29.97" spread="5.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.</title>
        <description>Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing</time_frame>
        <population>Pharmacodynamic (PD) population defined as all subjects who have evaluable DRQ-S values reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.</title>
          <description>Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.</description>
          <population>Pharmacodynamic (PD) population defined as all subjects who have evaluable DRQ-S values reported.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.0"/>
                    <measurement group_id="O2" value="1.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.60"/>
                    <measurement group_id="O2" value="2.0" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.75"/>
                    <measurement group_id="O2" value="2.0" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="8.28"/>
                    <measurement group_id="O2" value="2.2" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="8.33"/>
                    <measurement group_id="O2" value="2.5" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="6.04"/>
                    <measurement group_id="O2" value="2.3" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="5.78"/>
                    <measurement group_id="O2" value="1.5" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.78"/>
                    <measurement group_id="O2" value="1.3" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.06"/>
                    <measurement group_id="O2" value="1.4" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="3.93"/>
                    <measurement group_id="O2" value="1.3" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.81"/>
                    <measurement group_id="O2" value="1.2" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.74"/>
                    <measurement group_id="O2" value="1.3" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.62"/>
                    <measurement group_id="O2" value="1.1" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.72"/>
                    <measurement group_id="O2" value="1.0" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC</title>
        <description>Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing</time_frame>
        <population>PD population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC</title>
          <description>Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.</description>
          <population>PD population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.0"/>
                    <measurement group_id="O2" value="1.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.73"/>
                    <measurement group_id="O2" value="1.3" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.66"/>
                    <measurement group_id="O2" value="1.9" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="8.38"/>
                    <measurement group_id="O2" value="2.3" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="8.69"/>
                    <measurement group_id="O2" value="3.5" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="7.59"/>
                    <measurement group_id="O2" value="3.5" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="6.72"/>
                    <measurement group_id="O2" value="2.7" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="6.09"/>
                    <measurement group_id="O2" value="2.1" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.57"/>
                    <measurement group_id="O2" value="2.1" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="4.13"/>
                    <measurement group_id="O2" value="1.9" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.60"/>
                    <measurement group_id="O2" value="1.5" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.26"/>
                    <measurement group_id="O2" value="1.3" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="7.19"/>
                    <measurement group_id="O2" value="1.2" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.40"/>
                    <measurement group_id="O2" value="1.0" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC</title>
        <description>Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing</time_frame>
        <population>PD population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC</title>
          <description>Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.</description>
          <population>PD population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.0"/>
                    <measurement group_id="O2" value="1.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.49"/>
                    <measurement group_id="O2" value="2.1" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.67"/>
                    <measurement group_id="O2" value="2.0" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="8.03"/>
                    <measurement group_id="O2" value="1.8" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="8.37"/>
                    <measurement group_id="O2" value="1.4" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="6.39"/>
                    <measurement group_id="O2" value="1.4" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="5.78"/>
                    <measurement group_id="O2" value="1.2" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.54"/>
                    <measurement group_id="O2" value="1.3" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.18"/>
                    <measurement group_id="O2" value="1.3" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="4.13"/>
                    <measurement group_id="O2" value="1.3" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.02"/>
                    <measurement group_id="O2" value="1.2" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.78"/>
                    <measurement group_id="O2" value="1.1" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.80"/>
                    <measurement group_id="O2" value="1.2" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.48"/>
                    <measurement group_id="O2" value="1.0" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <time_frame>Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing</time_frame>
        <population>Safety population defined as subjects who take at least one dose of investigational medicinal product and have at least one post-dose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <population>Safety population defined as subjects who take at least one dose of investigational medicinal product and have at least one post-dose safety assessment.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.6" spread="10.79"/>
                    <measurement group_id="O2" value="115.3" spread="10.26"/>
                    <measurement group_id="O3" value="114.8" spread="11.29"/>
                    <measurement group_id="O4" value="113.9" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.8" spread="11.10"/>
                    <measurement group_id="O2" value="121.0" spread="10.46"/>
                    <measurement group_id="O3" value="121.7" spread="13.31"/>
                    <measurement group_id="O4" value="122.6" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.9" spread="12.81"/>
                    <measurement group_id="O2" value="122.2" spread="11.34"/>
                    <measurement group_id="O3" value="125.5" spread="10.14"/>
                    <measurement group_id="O4" value="124.7" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.6" spread="12.95"/>
                    <measurement group_id="O2" value="120.8" spread="11.71"/>
                    <measurement group_id="O3" value="125.2" spread="11.50"/>
                    <measurement group_id="O4" value="124.2" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.0" spread="12.69"/>
                    <measurement group_id="O2" value="122.4" spread="11.04"/>
                    <measurement group_id="O3" value="123.5" spread="13.25"/>
                    <measurement group_id="O4" value="119.2" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.4" spread="15.62"/>
                    <measurement group_id="O2" value="121.9" spread="12.04"/>
                    <measurement group_id="O3" value="122.2" spread="13.19"/>
                    <measurement group_id="O4" value="118.4" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.0" spread="11.68"/>
                    <measurement group_id="O2" value="118.1" spread="12.97"/>
                    <measurement group_id="O3" value="114.7" spread="11.19"/>
                    <measurement group_id="O4" value="115.6" spread="13.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" spread="12.84"/>
                    <measurement group_id="O2" value="112.6" spread="10.56"/>
                    <measurement group_id="O3" value="114.4" spread="10.81"/>
                    <measurement group_id="O4" value="113.6" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.7" spread="10.25"/>
                    <measurement group_id="O2" value="114.8" spread="11.81"/>
                    <measurement group_id="O3" value="115.1" spread="11.71"/>
                    <measurement group_id="O4" value="116.0" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.0" spread="10.53"/>
                    <measurement group_id="O2" value="114.5" spread="10.72"/>
                    <measurement group_id="O3" value="114.8" spread="11.06"/>
                    <measurement group_id="O4" value="116.1" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.14"/>
                    <measurement group_id="O2" value="5.2" spread="3.10"/>
                    <measurement group_id="O3" value="3.5" spread="0.97"/>
                    <measurement group_id="O4" value="3.3" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
          <population>PK population</population>
          <units>ng.h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="626.27" spread="198.982"/>
                    <measurement group_id="O2" value="473.70" spread="71.043"/>
                    <measurement group_id="O3" value="687.00" spread="196.906"/>
                    <measurement group_id="O4" value="472.35" spread="108.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="1.55"/>
                    <measurement group_id="O2" value="10.25" spread="1.36"/>
                    <measurement group_id="O3" value="10.4" spread="1.65"/>
                    <measurement group_id="O4" value="10.91" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <time_frame>Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <population>Safety population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" spread="6.68"/>
                    <measurement group_id="O2" value="74.1" spread="6.72"/>
                    <measurement group_id="O3" value="77.7" spread="8.60"/>
                    <measurement group_id="O4" value="75.8" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="6.62"/>
                    <measurement group_id="O2" value="76.4" spread="5.98"/>
                    <measurement group_id="O3" value="80.5" spread="9.52"/>
                    <measurement group_id="O4" value="80.4" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="6.97"/>
                    <measurement group_id="O2" value="75.4" spread="6.58"/>
                    <measurement group_id="O3" value="82.0" spread="6.44"/>
                    <measurement group_id="O4" value="81.9" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="7.91"/>
                    <measurement group_id="O2" value="77.7" spread="6.31"/>
                    <measurement group_id="O3" value="82.0" spread="7.68"/>
                    <measurement group_id="O4" value="82.0" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="7.87"/>
                    <measurement group_id="O2" value="74.1" spread="5.73"/>
                    <measurement group_id="O3" value="80.3" spread="9.54"/>
                    <measurement group_id="O4" value="79.2" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="9.45"/>
                    <measurement group_id="O2" value="78.5" spread="8.29"/>
                    <measurement group_id="O3" value="78.7" spread="10.47"/>
                    <measurement group_id="O4" value="77.8" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="6.76"/>
                    <measurement group_id="O2" value="76.8" spread="8.62"/>
                    <measurement group_id="O3" value="75.0" spread="7.76"/>
                    <measurement group_id="O4" value="75.4" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="8.39"/>
                    <measurement group_id="O2" value="73.5" spread="8.40"/>
                    <measurement group_id="O3" value="77.2" spread="6.53"/>
                    <measurement group_id="O4" value="74.4" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="7.97"/>
                    <measurement group_id="O2" value="74.7" spread="7.24"/>
                    <measurement group_id="O3" value="76.1" spread="7.58"/>
                    <measurement group_id="O4" value="77.9" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="8.02"/>
                    <measurement group_id="O2" value="75.7" spread="7.65"/>
                    <measurement group_id="O3" value="75.7" spread="7.48"/>
                    <measurement group_id="O4" value="78.3" spread="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <time_frame>Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <population>Safety population</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="9.87"/>
                    <measurement group_id="O2" value="69.0" spread="8.87"/>
                    <measurement group_id="O3" value="73.3" spread="10.16"/>
                    <measurement group_id="O4" value="71.4" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" spread="10.61"/>
                    <measurement group_id="O2" value="70.0" spread="11.29"/>
                    <measurement group_id="O3" value="73.4" spread="10.91"/>
                    <measurement group_id="O4" value="73.8" spread="13.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="11.64"/>
                    <measurement group_id="O2" value="75.2" spread="10.85"/>
                    <measurement group_id="O3" value="83.4" spread="14.68"/>
                    <measurement group_id="O4" value="80.5" spread="16.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="14.40"/>
                    <measurement group_id="O2" value="74.5" spread="12.62"/>
                    <measurement group_id="O3" value="84.4" spread="16.29"/>
                    <measurement group_id="O4" value="78.4" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" spread="11.38"/>
                    <measurement group_id="O2" value="79.1" spread="10.70"/>
                    <measurement group_id="O3" value="87.7" spread="14.34"/>
                    <measurement group_id="O4" value="81.5" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="13.84"/>
                    <measurement group_id="O2" value="82.3" spread="14.12"/>
                    <measurement group_id="O3" value="89.1" spread="13.77"/>
                    <measurement group_id="O4" value="82.7" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="11.19"/>
                    <measurement group_id="O2" value="74.7" spread="12.58"/>
                    <measurement group_id="O3" value="80.4" spread="11.32"/>
                    <measurement group_id="O4" value="76.4" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="11.28"/>
                    <measurement group_id="O2" value="74.0" spread="11.02"/>
                    <measurement group_id="O3" value="75.1" spread="10.32"/>
                    <measurement group_id="O4" value="75.0" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" spread="10.63"/>
                    <measurement group_id="O2" value="73.3" spread="9.16"/>
                    <measurement group_id="O3" value="72.0" spread="7.99"/>
                    <measurement group_id="O4" value="72.7" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="10.64"/>
                    <measurement group_id="O2" value="70.4" spread="9.11"/>
                    <measurement group_id="O3" value="72.5" spread="10.12"/>
                    <measurement group_id="O4" value="73.9" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.</description>
        <time_frame>Pre-dose, 2 and 8 hours after dosing</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Vyvanse</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR</title>
          </group>
          <group group_id="O3">
            <title>Vyvanse + Prilosec OTC</title>
          </group>
          <group group_id="O4">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.</description>
          <population>Safety population</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.8" spread="14.55"/>
                    <measurement group_id="O2" value="398.3" spread="15.24"/>
                    <measurement group_id="O3" value="399.3" spread="13.38"/>
                    <measurement group_id="O4" value="399.8" spread="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.0" spread="14.11"/>
                    <measurement group_id="O2" value="394.6" spread="13.42"/>
                    <measurement group_id="O3" value="397.9" spread="13.86"/>
                    <measurement group_id="O4" value="396.1" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390.0" spread="12.45"/>
                    <measurement group_id="O2" value="393.8" spread="13.94"/>
                    <measurement group_id="O3" value="395.4" spread="14.93"/>
                    <measurement group_id="O4" value="394.4" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
          <population>PK population</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" spread="2.022"/>
                    <measurement group_id="O2" value="8.10" spread="1.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="3.0"/>
                    <measurement group_id="O2" value="3.5" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <population>PK population</population>
          <units>ng.h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.28" spread="24.355"/>
                    <measurement group_id="O2" value="145.83" spread="38.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.98" spread="1.92"/>
                    <measurement group_id="O2" value="13.06" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>Total amphetamine is the d- and l-amphetamines.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>Total amphetamine is the d- and l-amphetamines.</description>
          <population>PK population</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.56" spread="9.188"/>
                    <measurement group_id="O2" value="38.05" spread="7.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>Total amphetamine is the d- and l-amphetamines.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>Total amphetamine is the d- and l-amphetamines.</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="3.07"/>
                    <measurement group_id="O2" value="3.29" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>Total amphetamine is the d- and l-amphetamines.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>Total amphetamine is the d- and l-amphetamines.</description>
          <population>PK population</population>
          <units>ng.h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="620.68" spread="95.689"/>
                    <measurement group_id="O2" value="620.91" spread="145.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
        <description>Total amphetamine is the d- and l-amphetamines.</description>
        <time_frame>0 through 96 hours after dosing</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR</title>
          </group>
          <group group_id="O2">
            <title>Adderall XR + Prilosec OTC</title>
          </group>
        </group_list>
        <measure>
          <title>T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC</title>
          <description>Total amphetamine is the d- and l-amphetamines.</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.38" spread="1.56"/>
                    <measurement group_id="O2" value="11.05" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vyvanse</title>
        </group>
        <group group_id="E2">
          <title>Adderall XR</title>
        </group>
        <group group_id="E3">
          <title>Vyvanse + Prilosec OTC</title>
        </group>
        <group group_id="E4">
          <title>Adderall XR + Prilosec OTC</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerald Tremblay, M.D.</name_or_title>
      <organization>Shire Pharmaceuticals</organization>
      <email>gtremblay@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

